MyCEI Login


Preventing Anal Cancer: Results from the ANCHOR Study


Published Date: 04/25/2022

Expiration Date: 03/22/2025

CE Credit: CME:1


Joel Palefsky,M.D., C.M., F.R.C.P.(C)

Joel Palefsky, M.D., C.M., F.R.C.P.(C). Professor of Medicine and Infectious Diseases at the University of California San Francisco School of Medicine. He is an internationally recognized expert on the molecular biology, treatment, pathogenesis and natural history of anogenital human papillomavirus infections, particularly in the setting of HIV infection. He is the director of the world's first clinic devoted to prevention of anal cancer, the Anal Neoplasia Clinic Research and Education Center at the UCSF Cancer Center. He is the vice-chair of the National Cancer Institute (NCI)-supported AIDS Malignancy Consortium. He is the chair of the Anal Cancer /HSIL Outcomes Research (ANCHOR) Study, a national multi-site NIH study designed to determine whether treatment of anal cancer precursor lesions prevents the development of anal cancer and to identify biomarkers of progression. He is founder and past president of the International Anal Neoplasia Society and is past president of the International Papillomavirus Society.

Learning Objectives

  • Understand the rationale for and design of the ANCHOR Study.
  • Know the results of the ANCHOR Study.
  • Be able to discuss the implications of the ANCHOR Study.

Continuing Education Credit Information